Oppenheimer raised the firm’s price target on CME Group (CME) to $258 from $245 and keeps an Outperform rating on the shares. The firm says CME set another record quarter, with Q3 adjusted EPS of $2.68 vs. its $2.61 and consensus’ $2.65. The uncertainty about the U.S. election and geopolitical environment has increased the demand for risk management, which provides tailwinds for CME, Oppenheimer adds.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME: